Carsen

CARsgen Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of chimeric antigen receptor (CAR) T-cell therapies for both hematologic malignancies and solid tumors. The company's lead product, zevorcabtagene autoleucel (CT053), is a BCMA-targeting CAR-T therapy that has received approval in China for the treatment of relapsed or refractory multiple myeloma. CARsgen is notably a pioneer in targeting solid tumors, with its CT041 candidate being the world's first Claudin 18.2-targeted CAR-T cell therapy to enter a confirmatory Phase 2 clinical trial. The company leverages several proprietary technology platforms, including CycloCAR for improved anti-tumor activity and THANK-uCAR for off-the-shelf allogeneic treatments. With integrated capabilities spanning discovery, clinical development, and internal GMP manufacturing in both China and the United States, CARsgen aims to provide curative treatments to cancer patients globally.